期刊文献+

抗KDR单链抗体阻断VEGF/KDR通路的活性研究 被引量:1

Research on Inhibition Activity of a Single Chain Fv (scFv) against Vascular Endothelial Growth Factor Receptor 2
原文传递
导出
摘要 为了阻断VEGF与KDR的结合,抑制VEGF结合KDR后介导的内皮细胞迁移和血管新生,实验室已经从全人源噬菌体展示抗体库中筛选得到几种抗KDR的单链抗体,从中挑选一种亲和力较高的抗体命名为AK506进行周质表达,纯化后经SDS-PAGE鉴定,可获得纯度为95%的电泳纯抗体,产量可以达到每升发酵液1 mg。经表面等离子共振技术测定,AK506与KDR胞外区相互作用的平衡解离常数为7.99×10-9nmol/L。细胞ELISA分析显示,AK506与内皮细胞表面膜受体KDR的结合呈剂量依赖性。采用细胞划痕损伤修复实验和鸡胚尿囊膜实验证明,AK506可以显著抑制内源性VEGF诱导的血管内皮细胞迁移和新血管生成,具有进一步研究开发用于抗肿瘤血管生成治疗的潜力。 In order to block the binding of vascular endothelial growth factor(VEGF) with vascular endothelial growth factor receptor 2(KDR),some single chain Fv(scFv) antibodied against KDR from full human phage display antibody library has been biopanned.One of them named AK506 which with higher affinity was expressed into the periplasmic space and purified by Ni-IMAC.The yield was 1 mg/L with purity of 95%.The surface plasmon resonance(SPR) technique and cell ELISA assay were adopted to test the interaction between AK506 and KDR,of which equilibrium dissociation rate constant(KD) was 7.99 nmol/L.The inhibition activities of AK506 on VEGF-induced endothelial cell proliferation and migration were studied using MTT assay and scratch-wound healing assay.Chorioallantoic membrane(CAM) assay was adopted to observe the antiangiogenic activity of AK506.The results showed that AK506 could bind with KDR on the surface of HUVEC cells and inhibit the binding of VEGF with KDR.According to these,AK506 can serve as a useful drug candidate in research,diagnostics and therapy of anti-angiogenesis tumor therapy.
出处 《药物生物技术》 CAS 2014年第1期7-12,共6页 Pharmaceutical Biotechnology
基金 国家自然科学基金资助项目(NSFC81072561 NSFC81102364 NSFC81273425) 江苏省普通高校研究生科研创新计划(No.CXZZ11_0818) 国家大学生创新性实验计划项目(No.G12071)
  • 相关文献

参考文献14

  • 1Folkman J. Tumor augiogenesis : therapeutic implications [ J ]. N Engl J Med, 1971,285 ( 21 ) : 1182.
  • 2Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor[J]. Endocr Rev,1997,18( 1 ) :4.
  • 3Tonini T, Rossi F, Clandio PP. Molecular basis of angiogenesis and cancer[ J]. Oncogene,2003,22(42) :6549.
  • 4Folkman J. Role of angiogenesis in tumor growth and metastasis [J]. Semin Oncol,2002,29(6 Suppl 16):15.
  • 5Carmeliet P. Mechanisms of angiogenesis and arteriogenesis [ J ]. Nat Med,2000 ,6( 4 ) :389.
  • 6Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identifica- tion of the KDR tyrosine kinase as a receptor for vascular endo- thelial cell growth factor [ J ]. Biochem Biophys Res Commun, 1992,187 ( 3 ) : 1579.
  • 7Boozer C, Kim G, Cong S, et al. Looking towards label-free biomo- lecular interaction analysis in a high-throughput format : a review of new surface plasmon resonance technologies [ J ]. Curr Opin Biotechnol, 2006,17 ( 4 ) :400.
  • 8Ribatti D. Chick embryo chorioallantoic membrane as a useful tool to study angiogenesis[ J]. Int Rev Cell Mol Biol,2008,270 :181.
  • 9Wickner W, Driessen A J, Hartl FU. The enzymology of protein translocation across the Escherichia coli plasma membrane [ J ]. Annu Rev Biochem, 1991,60 : 101.
  • 10Shinkai A, Ito M, Anazawa H, et al. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endo- thelial growth factor[J]. J Biol Chem,1998,273(47) :31283.

同被引文献17

  • 1Herbst RS. Review of epidermal growth factor receptor biology [ J ]. Int J Radiat Oncol Biol Phys,2004,59( Suppl 2) :21-26.
  • 2Zhang Z, Neiva KG, Lingen MW, et al. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of ~EG- FR1 and VEGFR2 [J]. Cell Death Differ, 2010, 17 (3): 499-512.
  • 3Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis [J]. Eur J Cancer,2001,37( Suppl 4) :$9-15.
  • 4Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signal- ling-in control of vascular function [ J ]. Nat Rev Mol Cell Biol, 2006,7:359-371.
  • 5Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resist- ance to the EGFR monoclonal antibody cetuximab [ J ]. Cancer Biol Ther,2011,11(9) :777-792.
  • 6Xie W,Li D,Zhang J,et al. Generation and characterization of anovel human IgG1 antibody against vascular endothelial growth factor receptor 2 [ J]. Cancer Immunol Immunother, 2014,63 (9) :877-888.
  • 7Grant S. Cotargeting survival signaling pathways in cancer[ J]. J Clin Invest, 2008,118 ( 9 ) : 3003-3006.
  • 8Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive path- way map of epidermal growth factor receptor signaling [ J ]. Mol Syst Bid,2005,1:2005. 0011.
  • 9Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial eval- uating the anti-vascular endothelial growth factor monoclonal anti- body bevacizumab in combination with the HER-l/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer [ J ]. J Clin Onco1,2005 ,23 :44-55.
  • 10Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevaelzumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study[ J ]. J Clin Onco1,2007 ,25:57-6l.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部